Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 12/20 | 0.56 |
| ▸ | APOB | P04114 | 11/20 | 0.56 |
| ▸ | SMO | Q99835 | 10/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288828 | 0.92 | MTTP (0.65) | MTTPAPOBSMO | |
| SCHEMBL3289592 | 0.92 | APOB (0.47) | MTTPAPOBSMO | |
| SCHEMBL3292088 | 0.89 | MTTP (0.48) | MTTPAPOB | |
| SCHEMBL3289795 | 0.88 | MTTP (0.58) | MTTPAPOBSMO | |
| SCHEMBL4075186 | 0.88 | SMO (0.56) | MTTPAPOBSMO | |
| SCHEMBL3289542 | 0.85 | MAPT (0.48) | MTTPAPOBSMO | |
| SCHEMBL3289889 | 0.84 | MAPT (0.45) | MTTPAPOB | |
| SCHEMBL3290189 | 0.83 | SMN1; SMN2 (0.51) | MTTPAPOB | |
| SCHEMBL3289470 | 0.83 | APOB (0.54) | MTTPAPOBSMO | |
| SCHEMBL3288697 | 0.82 | SMO (0.56) | MTTPAPOBSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | claimed |
| EP-1753721-B1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1753721-B1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | MTTP 202/4885APOB 23/4885SMO 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.